Barclays »

Sab Biotherapeutics shares owned by Barclays

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2024-09-30 $0 10 0.00

More positions owned by Barclays

SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Opt Put Option (QQQ)
Microsoft Corp Opt Call Option (MSFT)
Ishares Tr Opt Call Option (IWM)
Apple Opt Put Option (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Alphabet Inc Class A cs (GOOGL)
Tesla Opt Put Option (TSLA)
Ishares Tr Fund (HYG)
Facebook Inc cl a (META)
Berkshire Hathaway (BRK.B)
Broadcom (AVGO)
Visa (V)
Alphabet Opt Put Option (GOOG)

View all positions for Barclays

Top funds holding Sab Biotherapeutics

BVF
Marshall Wace
Sessa Capital IM
Vanguard Group
HB Wealth Management
Geode Capital Management
Pathstone Holdings
First Manhattan
BlackRock
First PREMIER Bank
Kovitz Investment Group Partners
Institutional & Family Asset Management
BlackRock
Kestra Advisory Services
Citadel Advisors

View all funds holding Sab Biotherapeutics